177 related articles for article (PubMed ID: 36433690)
1. Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma.
Haney SL; Feng D; Chhonker YS; Varney ML; Williams JT; Smith LM; Ford JB; Murry DJ; Holstein SA
Drug Dev Res; 2023 Feb; 84(1):62-74. PubMed ID: 36433690
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma.
Haney SL; Varney ML; Chhonker YS; Shin S; Mehla K; Crawford AJ; Smith HJ; Smith LM; Murry DJ; Hollingsworth MA; Holstein SA
Oncogene; 2019 Jun; 38(26):5308-5320. PubMed ID: 30918331
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
Haney SL; Wills VS; Wiemer DF; Holstein SA
Molecules; 2017 May; 22(6):. PubMed ID: 28555000
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.
Haney SL; Chhonker YS; Varney ML; Talmon G; Smith LM; Murry DJ; Holstein SA
J Pharmacol Exp Ther; 2019 Nov; 371(2):327-338. PubMed ID: 31420526
[TBL] [Abstract][Full Text] [Related]
6. Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma.
Haney SL; Varney ML; Williams JT; Smith LM; Talmon G; Holstein SA
Exp Hematol Oncol; 2022 Feb; 11(1):5. PubMed ID: 35139925
[TBL] [Abstract][Full Text] [Related]
7. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.
Muehlebach ME; Holstein SA
Clin Transl Med; 2023 Jan; 13(1):e1167. PubMed ID: 36650113
[TBL] [Abstract][Full Text] [Related]
8. Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.
Haney SL; Chhonker YS; Varney ML; Talmon G; Murry DJ; Holstein SA
Invest New Drugs; 2018 Oct; 36(5):810-818. PubMed ID: 29497895
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
Wasko BM; Dudakovic A; Hohl RJ
J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
[TBL] [Abstract][Full Text] [Related]
10. α-Amino bisphosphonate triazoles serve as GGDPS inhibitors.
Gehrke NR; Feng D; Ayub Ali M; Maalouf MA; Holstein SA; Wiemer DF
Bioorg Med Chem Lett; 2024 Apr; 102():129659. PubMed ID: 38373465
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers.
Waller DD; Park J; Tsantrizos YS
Crit Rev Biochem Mol Biol; 2019 Feb; 54(1):41-60. PubMed ID: 30773935
[TBL] [Abstract][Full Text] [Related]
12. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.
Agabiti SS; Liang Y; Wiemer AJ
Mol Membr Biol; 2016 Mar; 33(1-2):1-11. PubMed ID: 27537059
[TBL] [Abstract][Full Text] [Related]
14. α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Matthiesen RA; Varney ML; Xu PC; Rier AS; Wiemer DF; Holstein SA
Bioorg Med Chem; 2018 Jan; 26(2):376-385. PubMed ID: 29248353
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors.
Reilly JE; Zhou X; Tong H; Kuder CH; Wiemer DF; Hohl RJ
Biochem Pharmacol; 2015 Jul; 96(2):83-92. PubMed ID: 25952057
[TBL] [Abstract][Full Text] [Related]
16. Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.
Pham AC; Holstein SA; Borgstahl GEO
Mol Cancer Ther; 2024 Jan; 23(1):14-23. PubMed ID: 37756579
[TBL] [Abstract][Full Text] [Related]
17. ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.
Bhuiyan NH; Varney ML; Bhattacharya DS; Payne WM; Mohs AM; Holstein SA; Wiemer DF
Bioorg Med Chem Lett; 2019 Oct; 29(19):126633. PubMed ID: 31474482
[TBL] [Abstract][Full Text] [Related]
18. Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.
Allen C; Kortagere S; Tong H; Matthiesen RA; Metzger JI; Wiemer DF; Holstein SA
Mol Pharmacol; 2017 Mar; 91(3):229-236. PubMed ID: 28057800
[TBL] [Abstract][Full Text] [Related]
19. Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase.
Wills VS; Metzger JI; Allen C; Varney ML; Wiemer DF; Holstein SA
Bioorg Med Chem; 2017 Apr; 25(8):2437-2444. PubMed ID: 28302510
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
